Health & Fitness
Health and Fitness
Health and Fitness
Thu, February 26, 2009
Wed, February 25, 2009 Operations Executive Joins ReGen Biologics
HACKENSACK, N.J.--([ BUSINESS WIRE ])--ReGen Biologics (OTC: RGBO) ("ReGen") today announced the addition of Jay Flounlacker to the senior management team. He joins ReGen as the Senior Vice President, Administration. He will be responsible for coordinating operations across the Company among other senior executives to optimize Company resources to achieve training targets, sales and other goals.
His extensive healthcare background includes his most recent position as the Vice President for Service Delivery at DST Health Solutions, where he led a team of over 200 employees in the United States and India to provide implementation, consulting and technical support.
His experience also includes additional consulting and executive management positions at Epiphany Partners, Electronic Data Systems (EDS), First Consulting Group, APACHE Medical Systems, and Amisys Synertec.
Mr. Flounlacker previously worked with the ReGen management team on several consulting projects, and was involved with the Company's successful 510(k) application for the Menaflex™ collagen meniscus implant.
"We are extremely pleased to have Jay on the team again, this time on a full-time basis," said Gerald E. Bisbee, Jr., Ph.D., Chairman and CEO. "His expertise in project management and business process will be invaluable as we fully implement our Menaflex U.S. launch activities," Dr. Bisbee continued.
Mr. Flounlacker holds an Executive MBA from Loyola College, and a BA in English from the University of Maryland, where he served on the College of Arts and Humanities Alumni Board of Directors.
About ReGen Biologics, Inc.:
ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's first approved product using its proprietary biological collagen scaffold technology is the Menaflex™ collagen meniscus implant, which is cleared for sale in Europe and other countries and marketed through ReGen's European subsidiary, ReGen Biologics AG. ReGen received FDA clearance in the U.S. for the Menaflex device in December 2008. Visit [ www.regenbio.com ] and [ www.menaflex.com ] for more information.
